Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Partnershipmonoclonal antibody (mAb) biosimilarsantibody-drug conjugate (ADC) biosimilarsPositive

AI Analysis

Summary

Henlius and Sandoz announced a strategic collaboration covering up to 10 proposed monoclonal antibody and antibody-drug conjugate biosimilar assets, with the majority of programs in early development stages. The partnership is expected to generate revenue for Henlius in 2026.

Importance:7/10

Sentiment:

0.60

biosimilarsmonoclonal antibodyADCstrategic collaborationglobal partnership

Related Companies

$GBCYD $SDZ.SW

Read the original article

Published by PR Newswire Biotech on August 17, 2026 4:08 AM

Read Original